Drugs / QLH11906
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05488821 | Jun 2022 → Jul 2024 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLH11906 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05488821 ↗ |
| Route | Oral | “Oral Pan-RAF Inhibitor QLH11906” NCT05488821 ↗ |